# Lentitek

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lentitek

- Industry: Biotechnology
- Headquarters: Edinburgh, UK
- Website: www.lentitek.com/
- Total disclosed funding: $0.3M
- Latest round: Seed (May 9, 2023)
- Investors on record: 3

## About

Lentitek Ltd. is a biotechnology firm focused on the innovation of lentiviral vector manufacturing technologies, enhancing production efficiency for cell and gene therapies.Founded in 2019 in Edinburgh, UK, Lentitek Ltd. specializes in advancing lentiviral vector production methods. The company has engaged in three deals since inception, with their most recent deal occurring on March 5, 2025, where they raised GBP 700,000 in funding led by Equity Gap, alongside other investors. The founder, whose detailed history is not disclosed, brings expertise from prior ventures in the biotech sector.Lentitek specializes in the development of advanced lentiviral vector manufacturing technology aimed at enhancing the quality and yield of vectors used in cell and gene therapies, including CAR-T therapies. Their core product offerings focus on a proprietary method that utilizes a novel promoter, which effectively reduces vector genome splicing and minimizes payload breakthrough expression. This innovative technology is designed to cater to various production scenarios, as it supports both transient transfection and stable cell line production without necessitating modifications to the vector genomic sequence. The company primarily serves biopharmaceutical firms and research institutions engaged in the development of advanced therapy medicinal products (ATMPs) across global markets, including North America, Europe, and Asia.Lentitek's revenue model is predicated on establishing partnerships with biopharmaceutical companies and research institutions, facilitating the integration of their proprietary lentiviral vector production technology into existing manufacturing processes. Transactions typically occur through direct business-to-business agreements, where clients engage Lentitek for technology licensing, collaborative research efforts, and customized production solutions tailored to their specific needs. The company may offer pricing structures based on service agreements or project scopes, with potential options for long-term contracts to ensure consistent supply and support for clients’ manufacturing requirements. As Lentitek continues to innovate and expand its offerings, the revenue streams will reflect the growing demand for high-quality lentiviral vectors in the rapidly evolving gene therapy landscape.In March 2025, Lentitek Ltd. raised GBP 700,000 in venture funding led by Equity Gap, with participation from Apollo Informal Investment, Gabriel Investments, and Scottish Enterprise. The company will use this funding to advance development and commercialization of viral vector technology for cancer treatments. Lentitek plans to design and launch new products targeting the gene therapy market while expanding its operations into new regions, particularly in North America and Asia, by the end of 2026.

## Funding rounds

- Seed, May 9, 2023, $0.3M — Old College Capital, Gabriel Investments, Apollo Informal Investment

## Investors

- Old College Capital (https://capitalatlas.ai/funds/old-college-capital) — Seed
- Gabriel Investments (https://capitalatlas.ai/funds/gabriel-investments) — Seed
- Apollo Informal Investment — Seed